Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Independent sales representatives provide scalable technology sales opportunity for health screening and vaccine passports to Contakt World and its portfolio companies

HealthCheck's existing 1,000+ customer sites were acquired through sales efforts of one part-time independent sales representative and two founders leading to $1.55M CAD revenue and $555K CAD net profit for the twelve-months ended July 31, 2021¹

In addition to plans to bolster its revenue opportunities with vaccine passports and validation, Contakt World just launched a program to aggressively add independent sales representatives to scale sales within employer establishments, K-12 schools and event venues in the US

Contakt World's advertisements and initial screening process to add independent sales representatives for health screening, vaccine passports, and future solutions yielded dozens of qualified applicants in less than two weeks

Independent sales representatives are expected to grow customer base and increase revenue for HealthCheck and future solutions like vaccine passports on a commission-only basis

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges like symptom screening and vaccine passports, today announced it will create a network of independent sales representatives to scale sales for the recently acquired HealthCheck app, vaccine passports, and future acquisitions or partnering products.

Contakt World's processes for independent sales representatives are being designed for efficient onboarding, CRM to track leads and sales, recurring trainings, and lead generation to support independent sales representatives. Independent sales representatives will be paid a commission of 10% on their collected sales from health screening, vaccine passports, and future products.

"A single independent sales representative working on a commission-basis led to hundreds of commercial users for HealthCheck and 12-month trailing revenues of $1.55M CAD¹, as at July 31, 2021, before we acquired the company," stated Justin Beck, Chief Visionary Officer for Contakt World. "HealthCheck is an attractive solution for organizations of all shapes and sizes, where liabilities relating to COVID-19, vaccine passports, symptom screening, and safety are reduced through our SaaS solutions. More independent representatives to sell our solutions means more sales opportunities for Contakt World." Contakt has initiated the onboarding of several sales representatives with the goal of contracting a team of 15-20 people in the next 30-60 days distributed across multiple states in the United States.

In addition to its efforts to add vaccine credentials and vaccine validation to the HealthCheck screening tool, Contakt World is negotiating with several partner technologies to bolster its SaaS portfolio for customers in a number of health-related fields. Symptom screening, vaccine passports, vaccine validation, and other methods to improve population safety and reduce liability are becoming key to everyday business, travel, and social life.

Other Recent Related News from Contakt World:

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

To Learn More:

To receive investor updates from Contakt World Technologies Corp. including its efforts in the field of vaccine passports, click here.

If you are an organization seeking daily health screening and future vaccine passports, schedule a demo of HealthCheck by clicking here.

About Contakt World

Contakt World's mission is to develop or acquire and deliver software (SaaS) that improves access to, efficiencies within, and quality of healthcare in all its forms. Contakt World envisions a world where everyone can achieve their full health potential, and no one is disadvantaged from achieving this potential because of social position or other circumstances. Contakt World's portfolio presently includes the award-winning software platform, Smart Health RM, and HealthCheck by Stratum which is used in over 1,000 locations. For more information, please visit https://contakt.world/.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: Healthcheck's integration into Contakt World's offerings, business plan and growth strategy; Healthchecks's prospects as a platform and service; Contakt World's ability to scale and sell HealthCheck, including through its new sales representative program; Contakt Worlds's work to bolster its SaaS portfolio; Contakt World's ability to deploy a successful vaccine passport; and Contakt World's ability to leverage Healthcheck going forward. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

^{____________________}

¹ Unaudited, based on management prepared financial information for the 12-months ending July 31,2021 using 1 USD to 1.26 CAD exchange rate on August 31, 2021.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95097

News Provided by Newsfile via QuoteMedia

Contakt World CSE:HELP Emerging Tech Investing

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.